InMed Pharmaceuticals (INM) Operating Margin (2021 - 2025)
Historic Operating Margin for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 256.36%.
- InMed Pharmaceuticals' Operating Margin fell 536000.0% to 256.36% in Q4 2025 from the same period last year, while for Dec 2025 it was 174.87%, marking a year-over-year decrease of 120500.0%. This contributed to the annual value of 160.77% for FY2025, which is 175000.0% up from last year.
- Per InMed Pharmaceuticals' latest filing, its Operating Margin stood at 256.36% for Q4 2025, which was down 536000.0% from 162.54% recorded in Q3 2025.
- In the past 5 years, InMed Pharmaceuticals' Operating Margin ranged from a high of 20.99% in Q2 2023 and a low of 1626.64% during Q4 2021
- Moreover, its 5-year median value for Operating Margin was 202.75% (2024), whereas its average is 450.84%.
- As far as peak fluctuations go, InMed Pharmaceuticals' Operating Margin skyrocketed by 12456200bps in 2023, and later crashed by -1375500bps in 2024.
- Over the past 5 years, InMed Pharmaceuticals' Operating Margin (Quarter) stood at 1626.64% in 2021, then skyrocketed by 71bps to 471.26% in 2022, then skyrocketed by 72bps to 132.64% in 2023, then plummeted by -53bps to 202.75% in 2024, then dropped by -26bps to 256.36% in 2025.
- Its Operating Margin stands at 256.36% for Q4 2025, versus 162.54% for Q3 2025 and 139.49% for Q2 2025.